SUBSCRIBE
SUBSCRIBE
News   Business

Nisshin Kyorin Pharmaceutical, Yakult To Form Marketing Alliance For 5-HT3 Receptor Antagonist

October 19, 2005 | 
1 min read
Nisshin Kyorin Pharmaceutical announced on August 24 that it has concluded a cooperative sales agreement with Yakult Honsha for "Sinseron Tablet 8 mg," a serotonin 5-HT3 receptor antagonist with antiemetic property.
Alliances
MORE ON THIS TOPIC
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Massachusetts-Based Karyopharm, Azurity Cut Workforces
July 14, 2025
 · 
158 min read
 · 
BioSpace Editorial Staff
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac